Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2009

Alnara Gains Rights to Late-Stage Pancreatic Treatment from the Cystic Fibrosis Foundation

Alnara Gains Rights to Late-Stage Pancreatic Treatment from the Cystic Fibrosis Foundation

Liprotamase to help improve condition of CF patients

  • Alnara Pharmaceuticals entered a licensing agreement with the Cystic Fibrosis Foundation Therapeutics for the worldwide rights to liprotamase, an oral, porcine-free pancreatic enzyme replacement therapy (PERT). The treatment has completed a Phase III efficiency trial that reportedly showed improvement in fat and protein absorption in CF patients who took liprotamase.

    PERT is used to treat the pancreatic insufficiency, common in patients with cystic fibrosis and chronic pancreatitis, which prevents them from properly absorbing nutrients from food.

    "Liprotamase has the potential to significantly advance the treatment of pancreatic insufficiency, and Alnara plans to complete development, seek FDA approval, and make it available to patients," says Alexey Margolin, Ph.D., president and CEO of Alnara.

    The Cystic Fibrosis Foundation has reportedly invested more than $300 million in drug research with biotech companies since 1998 for CF treatments.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »